All‐cause mortality · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)
Alirocumab leads to lower all‐cause mortality compared with placebo (high certainty).
1 finding from 1 review
Myocardial infarction · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)
Alirocumab leads to lower myocardial infarction compared with placebo (high certainty).
1 finding from 1 review
Stroke · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)
Alirocumab leads to lower any stroke compared with placebo (high certainty).
1 finding from 1 review
CVD · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)
Evolocumab leads to lower CVD compared with placebo (high certainty).
1 finding from 1 review
All‐cause mortality · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)
Evolocumab showed no clear difference in all‐cause mortality compared with placebo (high certainty).
1 finding from 1 review
Myocardial infarction · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)
Evolocumab leads to lower myocardial infarction compared with placebo (high certainty).
1 finding from 1 review
Stroke · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)
Evolocumab leads to lower any stroke compared with placebo (high certainty).
1 finding from 1 review
CVD · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)
Alirocumab showed no clear difference in CVD compared with ezetimibe and statins (low certainty).
1 finding from 1 review
Adverse effects · Adults with head and neck cancer undergoing curative or adjuvant radiotherapy (at risk of osteoradionecrosis of the jaws)
1 finding from 1 review
Adverse effects were an outcome of interest in the study conducting this comparison, however no mention was made of the presence or absence of any adverse events
1 study · 220 participants
Very low
Intervention not reported
All‐cause mortality: up to 3 months' · participants with alcoholic hepatitis at high risk of mortality and morbidity
It is very uncertain whether the intervention changes all‐cause mortality: up to 3 months' (very low certainty).
1 finding from 1 review
Intervention not reported
Health‐related quality of life: up to 3 months ( · participants with alcoholic hepatitis at high risk of mortality and morbidity
The intervention showed no clear difference in health‐related quality of life: up to 3 months ( (low certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events during treatment · participants with alcoholic hepatitis at high risk of mortality and morbidity
It is very uncertain whether the intervention changes serious adverse events during treatment (very low certainty).
1 finding from 1 review
Intervention not reported
Liver‐related mortality: up to 3 months' · participants with alcoholic hepatitis at high risk of mortality and morbidity
It is very uncertain whether the intervention changes liver‐related mortality: up to 3 months' (very low certainty).
1 finding from 1 review
Intervention not reported
Participants with any complication: up to 3 months following randomisation · participants with alcoholic hepatitis at high risk of mortality and morbidity
It is very uncertain whether the intervention changes participants with any complication: up to 3 months following… (very low certainty).
1 finding from 1 review
Intervention not reported
Participants with non‐serious adverse events: up to 3 months' · participants with alcoholic hepatitis at high risk of mortality and morbidity
It is very uncertain whether the intervention changes participants with non‐serious adverse events: up to 3 months' (very low certainty).
1 finding from 1 review
Survival to hospital discharge · people suffering cardiac arrest
It is very uncertain whether standard‐dose adrenaline (SDA) changes survival to hospital discharge compared with high‐dose adrenaline (HDA) (very low certainty).
1 finding from 1 review
Survival to hospital admission · people suffering cardiac arrest
It is very uncertain whether standard‐dose adrenaline (SDA) changes survival to hospital admission compared with high‐dose adrenaline (HDA) (very low certainty).
1 finding from 1 review
Favourable neurological outcomes · people suffering cardiac arrest
It is very uncertain whether standard‐dose adrenaline (SDA) changes favourable neurological outcomes compared with high‐dose adrenaline (HDA) (very low certainty).
1 finding from 1 review
Return of spontaneous circulation · people suffering cardiac arrest
It is very uncertain whether standard‐dose adrenaline (SDA) changes return of spontaneous circulation compared with high‐dose adrenaline (HDA) (very low certainty).
1 finding from 1 review
Occurrence of intraoperative awareness Time points of measure after surgery: 2 to 6 hours;12 hours; 1 day; 2 days; 3 days; 14 days; 30 days; or time point was not reported Measurement tools: simple questioning; interviews; or structured questionna... · adults undergoing surgery with general anaesthesia
Bispectral index may leads to lower occurrence of intraoperative awareness Time points of measure after… compared with clinical signs (low certainty).
1 finding from 1 review